Last reviewed · How we verify

Ephedrine Hydrochloride 3 MG/ML

University Hospital, Ghent · FDA-approved active Small molecule Quality 55/100

Ephedrine Hydrochloride 3 MG/ML is a marketed sympathomimetic amine developed by University Hospital, Ghent, indicated for hypotension management during anesthesia and bronchial asthma treatment. The drug functions as a dual α- and β-adrenergic receptor agonist while indirectly stimulating norepinephrine release from sympathetic neurons. With 37 clinical trials completed and no published literature, the product represents an established therapeutic option in anesthesia and respiratory care. As a marketed formulation, it has established clinical utility but limited recent commercial development or pipeline expansion. The drug's mechanism provides rapid hemodynamic support and bronchodilation through multiple adrenergic pathways, making it valuable in acute clinical settings.

At a glance

Generic nameEphedrine Hydrochloride 3 MG/ML
SponsorUniversity Hospital, Ghent
Drug classSympathomimetic amine; adrenergic agonist
Targetα-adrenergic receptors (α1, α2) and β-adrenergic receptors (β1, β2); sympathetic nerve terminals
ModalitySmall molecule
Therapeutic areaNeuroscience
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: